Salarius obtains dose-escalation milestones for its Seclidemstat trial
sarcoma is a type of bone cancer that can also appear in fat, muscle, deep skin tissues, blood vessels, tendons, ligaments and cartilage. Moreover, there are over 70 types of sarcoma, with each treatment varying from the other, depending on various factors like location and type. Salarius Pharmaceuticals, Inc., recently made some significant developments in this regard, announcing that the Safety Review Committees monitoring the Phase 1 trials of Seclidemstat in patients with AST (advanced solid tumors) and the Phase 1/2 clinical trial of Seclidemstat in Ewing sarcoma have cleared the developments of each trial to the fourth stage of dosing. According to reliable sources, both the clinical studies were designed as a dose-finding open-label studies to understand the initial safety profile of Seclidemstat and establish the maximum tolerated dose (MTD). Additionally, Seclidemstat, which was administered every day as an oral tablet, with each test group getting a heightened dose of study drug, will later be administered to a bigger group of patients so as to confirm its safety profile. Reportedly the firm aims to gather additional information regarding potential preliminary efficacy and pharmacokinetics. Speaking on the development, David Arthur, President and Chief Executive Officer, Salarius, said that an approval from the Safety Review Committees to go ahead with a higher dosing cohort marks a significant landmark for the ongoing clinical studies, as well as the company. Arthur further added, ultimately, the endpoint of these studies is to identify the ideal dose of Seclidemstat, as well as establishing the drug’s safety parameters. Evidently, according to the current estimates the company is on track to achieve MTD by early next year and intends to report initial patient data in 2020. Change in Management Meanwhile, the company recently made headlines, when it announced its new Chief Business Officer and Executive Vice President Finance. According to the latest reports, Scott Jordan will fulfill the role of Chief Business Officer while Mark Rosenblum will act as the Executive Vice President Finance and also fill the shoes of Interim Chief Financial Officer. Reportedly, the move plans to improve the company’s focus on strategic value creation and financial operations while its clinical programs in advanced solid tumors and Ewing sarcoma advance towards achieving potential data milestones by 2020. Source Credit: http://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-achieves-dose-escalation-milestones